Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Smith Discusses CAR T Cell Persistence in Myeloma

Eric Smith, MD, PhD
Published: Thursday, Nov 01, 2018



Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric antigen receptor (CAR) T cell persistence in patients with multiple myeloma.

Smith says that a way to advance CAR T-cell therapy for patients with myeloma is with novel CAR T-cell vectors that enhance the depth and persistence of responses for patients. In myeloma, multiple studies with CD19 and BCMA CAR T cells have shown that the expansion and persistence of the gene-modified T cells correlate with deeper and more durable responses, he adds.

The reason that Smith says persistence is important is because a proportion of patients with myeloma are relapsing after CAR T-cell therapy. One reason for this relapse is that the target antigen gets downregulated or is not expressed in a small population of cells, and those cells end up growing out. For that reason, Smith says that investigators are looking at dual targeting.


Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric antigen receptor (CAR) T cell persistence in patients with multiple myeloma.

Smith says that a way to advance CAR T-cell therapy for patients with myeloma is with novel CAR T-cell vectors that enhance the depth and persistence of responses for patients. In myeloma, multiple studies with CD19 and BCMA CAR T cells have shown that the expansion and persistence of the gene-modified T cells correlate with deeper and more durable responses, he adds.

The reason that Smith says persistence is important is because a proportion of patients with myeloma are relapsing after CAR T-cell therapy. One reason for this relapse is that the target antigen gets downregulated or is not expressed in a small population of cells, and those cells end up growing out. For that reason, Smith says that investigators are looking at dual targeting.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x